Evidence map›Paper›PMID 41226973›Full record

ArticleJournal of clinical medicine2025

Pentosidine and Bone Properties in Autosomal Dominant Polycystic Kidney Disease.

Magdalena Jankowska, Abdul Rashid Qureshi, Mathias Haarhaus, Per Magnusson, Alicja Dębska-Ślizień, Peter Barany, Olof Heimburger, Peter Stenvinkel, Bengt Lindholm

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Magdalena JankowskaDepartment of Nephrology, Transplantology and Internal Medicine, Faculty of Medicine, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0002-2432-6350
Abdul Rashid QureshiDivision of Renal Medicine and Baxter Novum, Karolinska Institute, 171 77 Stockholm, Sweden.ORCID 0000-0003-0536-5327
Mathias HaarhausDivision of Renal Medicine and Baxter Novum, Karolinska Institute, 171 77 Stockholm, Sweden.ORCID 0000-0001-8274-6356
Per MagnussonDepartment of Clinical Chemistry, and Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.ORCID 0000-0002-2123-7838
Alicja Dębska-ŚlizieńDepartment of Nephrology, Transplantology and Internal Medicine, Faculty of Medicine, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0001-8210-8063
Peter BaranyDivision of Renal Medicine and Baxter Novum, Karolinska Institute, 171 77 Stockholm, Sweden.
Olof HeimburgerDivision of Renal Medicine and Baxter Novum, Karolinska Institute, 171 77 Stockholm, Sweden.
Peter StenvinkelDivision of Renal Medicine and Baxter Novum, Karolinska Institute, 171 77 Stockholm, Sweden.ORCID 0000-0002-8785-4820
Bengt LindholmDivision of Renal Medicine and Baxter Novum, Karolinska Institute, 171 77 Stockholm, Sweden.ORCID 0000-0003-4269-4293

Funding

National Science Centre 2018/30/M/NZ5/00480
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced glycation end-productsbone-specific alkaline phosphatasebone strengthcollagen cross-linkingkidney diseases

Identifiers

PMID41226973
PMCPMC12608610

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.